<DOC>
	<DOC>NCT02534506</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.</brief_summary>
	<brief_title>Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Subjects with previously treated advanced malignant solid tumor Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 1 For certain subjects, willing and able to provide pretreatment tumor sample Known or suspected central nervous system metastases or central nervous system as the only source of disease Other concomitant malignancies (with some exceptions per protocol) Active, known or suspected autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Advanced malignant tumors</keyword>
	<keyword>Metastatic malignant tumors</keyword>
</DOC>